DexCom, Inc. (DXCM) SEC Filings
Filing links are provided when reliable SEC filing data is available.
Recent Filings
| Form | Filing Date | Accepted | Document |
|---|---|---|---|
| 4 | Jun 5, 2026 | Jun 5, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 4 | Jun 1, 2026 | Jun 1, 2026 | View filing |
| 8-K | May 28, 2026 | May 28, 2026 | View filing |
| SD | May 28, 2026 | May 28, 2026 | View filing |
| 4 | May 27, 2026 | May 27, 2026 | View filing |
| 4 | May 27, 2026 | May 27, 2026 | View filing |
| 4 | May 27, 2026 | May 27, 2026 | View filing |
| 4 | May 27, 2026 | May 27, 2026 | View filing |
| 4 | May 27, 2026 | May 27, 2026 | View filing |
| 4 | May 26, 2026 | May 26, 2026 | View filing |
| 4 | May 19, 2026 | May 19, 2026 | View filing |
| 8-K | May 15, 2026 | May 14, 2026 | View filing |
| 4 | May 14, 2026 | May 14, 2026 | View filing |
| 4 | May 11, 2026 | May 11, 2026 | View filing |
| 4 | May 11, 2026 | May 11, 2026 | View filing |
| 4 | May 11, 2026 | May 11, 2026 | View filing |
| 4 | May 11, 2026 | May 11, 2026 | View filing |
| 10-Q | Apr 30, 2026 | Apr 30, 2026 | View filing |
| 8-K | Apr 30, 2026 | Apr 30, 2026 | View filing |
| SC 13G | Apr 29, 2026 | Apr 29, 2026 | View filing |
| SC 13G | Apr 29, 2026 | Apr 29, 2026 | View filing |
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach